Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 2, 2008, Pages 178-179

  Sniecinski, Roman M ^a   Chen, Edward P ^a   Tanaka, Kenichi A ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Cardiothoracic Anesthesia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; FIBRIN; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOMODULIN;

BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HEART SURGERY; HUMAN; LETTER; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION;

ANTITHROMBIN III; CARDIOPULMONARY BYPASS; FIBRIN; HEMOSTASIS; HUMANS; POSTOPERATIVE HEMORRHAGE;

EID: 39149091682     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282f40d4a     Document Type: Letter

References (14)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385-391.
2. Mosesson MW. Update on antithrombin I (fibrin). Thromb Haemost 2007; 98:105-108.
3. Augoustides JG, Lin J, Gambone AJ, Cheung AT. Fatal thrombosis in an adult after thoracoabdominal aneurysm repair with aprotinin and deep hypothermic circulatory arrest. Anesthesiology 2005; 103:215-216.
4. Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa. Blood 2004; 104:123-127.
5. Chun R, Poon C, Haigh J, Seal D, Donahue B, Royston D. Case 1-2005: cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease. J Cardiothorac Vasc Anesth 2005; 19:109-117.
6. Aritomi M, Watanabe N, Ohishi R, Gomi K, Kiyota T, Yamamoto S, et al. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: thrombomodulin associates with free thrombin and is recycled to activate protein C. Thromb Haemost 1993; 70:418-422.
7. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106:2605-2612.
8. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991; 77:542-550.
9. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106:385-392.
10. Blome M, Isgro F, Kiessling AH, Skuras J, Haubelt H, Hellstern P, Saggau W. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93:1101-1107.
11. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005; 33:355-360.
12. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44:1143-1148.
13. Sniecinski RM, Chen EP, Levy JH, Szlam F, Tanaka KA. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. Anesth Analg 2007; 104:763-765.
14. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Miles Braun M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298.